ID   KPCD2_RAT               Reviewed;         875 AA.
AC   Q5XIS9;
DT   28-NOV-2006, integrated into UniProtKB/Swiss-Prot.
DT   23-NOV-2004, sequence version 1.
DT   02-OCT-2024, entry version 162.
DE   RecName: Full=Serine/threonine-protein kinase D2;
DE            EC=2.7.11.13 {ECO:0000250|UniProtKB:Q9BZL6};
DE   AltName: Full=nPKC-D2;
GN   Name=Prkd2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [2]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-197; SER-203; SER-211;
RP   SER-214 AND SER-711, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Serine/threonine-protein kinase that converts transient
CC       diacylglycerol (DAG) signals into prolonged physiological effects
CC       downstream of PKC, and is involved in the regulation of cell
CC       proliferation via MAPK1/3 (ERK1/2) signaling, oxidative stress-induced
CC       NF-kappa-B activation, inhibition of HDAC7 transcriptional repression,
CC       signaling downstream of T-cell antigen receptor (TCR) and cytokine
CC       production, and plays a role in Golgi membrane trafficking,
CC       angiogenesis, secretory granule release and cell adhesion. May
CC       potentiate mitogenesis induced by the neuropeptide bombesin by
CC       mediating an increase in the duration of MAPK1/3 (ERK1/2) signaling,
CC       which leads to accumulation of immediate-early gene products including
CC       FOS that stimulate cell cycle progression. In response to oxidative
CC       stress, is phosphorylated at Tyr-438 and Tyr-718 by ABL1, which leads
CC       to the activation of PRKD2 without increasing its catalytic activity,
CC       and mediates activation of NF-kappa-B. In response to the activation of
CC       the gastrin receptor CCKBR, is phosphorylated at Ser-244 by CSNK1D and
CC       CSNK1E, translocates to the nucleus, phosphorylates HDAC7, leading to
CC       nuclear export of HDAC7 and inhibition of HDAC7 transcriptional
CC       repression of NR4A1/NUR77. Upon TCR stimulation, is activated
CC       independently of ZAP70, translocates from the cytoplasm to the nucleus
CC       and is required for interleukin-2 (IL2) promoter up-regulation. During
CC       adaptive immune responses, is required in peripheral T-lymphocytes for
CC       the production of the effector cytokines IL2 and IFNG after TCR
CC       engagement and for optimal induction of antibody responses to antigens.
CC       In epithelial cells stimulated with lysophosphatidic acid (LPA), is
CC       activated through a PKC-dependent pathway and mediates LPA-stimulated
CC       interleukin-8 (IL8) secretion via a NF-kappa-B-dependent pathway.
CC       During TCR-induced T-cell activation, interacts with and is activated
CC       by the tyrosine kinase LCK, which results in the activation of the NFAT
CC       transcription factors. In the trans-Golgi network (TGN), regulates the
CC       fission of transport vesicles that are on their way to the plasma
CC       membrane and in polarized cells is involved in the transport of
CC       proteins from the TGN to the basolateral membrane. Plays an important
CC       role in endothelial cell proliferation and migration prior to
CC       angiogenesis, partly through modulation of the expression of KDR/VEGFR2
CC       and FGFR1, two key growth factor receptors involved in angiogenesis. In
CC       secretory pathway, is required for the release of chromogranin-A
CC       (CHGA)-containing secretory granules from the TGN. Downstream of PRKCA,
CC       plays important roles in angiotensin-2-induced monocyte adhesion to
CC       endothelial cells. {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13;
CC         Evidence={ECO:0000250|UniProtKB:Q9BZL6};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.13; Evidence={ECO:0000250|UniProtKB:Q9BZL6};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:Q9BZL6};
CC   -!- ACTIVITY REGULATION: Activated by DAG and phorbol esters. Phorbol-
CC       ester/DAG-type domains bind DAG, mediating translocation to membranes.
CC       Autophosphorylation of Ser-711 and phosphorylation of Ser-707 by PKC
CC       relieves auto-inhibition by the PH domain. Catalytic activity is
CC       further increased by phosphorylation at Tyr-718 in response to
CC       oxidative stress. {ECO:0000250|UniProtKB:Q9BZL6}.
CC   -!- SUBUNIT: Interacts (via C-terminus) with LCK. Interacts (via N-terminus
CC       and zing-finger domain 1 and 2) with PRKCD in response to oxidative
CC       stress; the interaction is independent of PRKD2 tyrosine
CC       phosphorylation. {ECO:0000250|UniProtKB:Q9BZL6}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q9BZL6}. Cell
CC       membrane {ECO:0000250|UniProtKB:Q15139}. Golgi apparatus, trans-Golgi
CC       network {ECO:0000250|UniProtKB:Q9BZL6}. Note=Translocation to the cell
CC       membrane is required for kinase activation. Accumulates in the nucleus
CC       upon CK1-mediated phosphorylation after activation of G-protein-coupled
CC       receptors. Nuclear accumulation is regulated by blocking nuclear export
CC       of active PRKD2 rather than by increasing import.
CC       {ECO:0000250|UniProtKB:Q9BZL6}.
CC   -!- PTM: Phosphorylation of Ser-873 correlates with the activation status
CC       of the kinase. Ser-707 is probably phosphorylated by PKC.
CC       Phosphorylation at Ser-244 by CSNK1D and CSNK1E promotes nuclear
CC       localization and substrate targeting. Phosphorylation at Ser-244, Ser-
CC       707 and Ser-711 is required for nuclear localization. Phosphorylated at
CC       Tyr-438 by ABL1 in response to oxidative stress. Phosphorylated at Tyr-
CC       718 by ABL1 specifically in response to oxidative stress; requires
CC       prior phosphorylation at Ser-707 or/and Ser-711.
CC       {ECO:0000250|UniProtKB:Q9BZL6}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. PKD subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BC083592; AAH83592.1; -; mRNA.
DR   RefSeq; NP_001013917.1; NM_001013895.1.
DR   AlphaFoldDB; Q5XIS9; -.
DR   SMR; Q5XIS9; -.
DR   STRING; 10116.ENSRNOP00000022360; -.
DR   iPTMnet; Q5XIS9; -.
DR   PhosphoSitePlus; Q5XIS9; -.
DR   PaxDb; 10116-ENSRNOP00000022360; -.
DR   Ensembl; ENSRNOT00000022360.6; ENSRNOP00000022360.3; ENSRNOG00000016434.6.
DR   Ensembl; ENSRNOT00055054123; ENSRNOP00055044762; ENSRNOG00055031225.
DR   Ensembl; ENSRNOT00060038398; ENSRNOP00060031666; ENSRNOG00060022147.
DR   Ensembl; ENSRNOT00065055289; ENSRNOP00065045480; ENSRNOG00065032097.
DR   GeneID; 292658; -.
DR   KEGG; rno:292658; -.
DR   UCSC; RGD:1308054; rat.
DR   AGR; RGD:1308054; -.
DR   CTD; 25865; -.
DR   RGD; 1308054; Prkd2.
DR   eggNOG; KOG4236; Eukaryota.
DR   GeneTree; ENSGT00950000183024; -.
DR   HOGENOM; CLU_009772_1_0_1; -.
DR   InParanoid; Q5XIS9; -.
DR   OMA; WVVHYSS; -.
DR   OrthoDB; 2939922at2759; -.
DR   PhylomeDB; Q5XIS9; -.
DR   TreeFam; TF314320; -.
DR   PRO; PR:Q5XIS9; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   Bgee; ENSRNOG00000016434; Expressed in thymus and 19 other cell types or tissues.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; ISO:RGD.
DR   GO; GO:0005080; F:protein kinase C binding; ISO:RGD.
DR   GO; GO:0106310; F:protein serine kinase activity; ISO:RGD.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISO:RGD.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; ISO:RGD.
DR   GO; GO:0035556; P:intracellular signal transduction; ISO:RGD.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; ISS:UniProtKB.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; ISO:RGD.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; ISS:UniProtKB.
DR   GO; GO:2000573; P:positive regulation of DNA biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; ISS:UniProtKB.
DR   GO; GO:2001028; P:positive regulation of endothelial cell chemotaxis; ISO:RGD.
DR   GO; GO:0038033; P:positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; ISS:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0045743; P:positive regulation of fibroblast growth factor receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0032743; P:positive regulation of interleukin-2 production; ISS:UniProtKB.
DR   GO; GO:0032757; P:positive regulation of interleukin-8 production; ISS:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0050862; P:positive regulation of T cell receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0030949; P:positive regulation of vascular endothelial growth factor receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0070232; P:regulation of T cell apoptotic process; ISO:RGD.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; ISO:RGD.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; ISO:RGD.
DR   CDD; cd20840; C1_PKD2_rpt1; 1.
DR   CDD; cd20843; C1_PKD2_rpt2; 1.
DR   CDD; cd01239; PH_PKD; 1.
DR   CDD; cd14082; STKc_PKD; 1.
DR   Gene3D; 3.30.60.20; -; 2.
DR   Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1.
DR   Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1.
DR   InterPro; IPR046349; C1-like_sf.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR015727; Protein_Kinase_C_mu-related.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR22968; PROTEIN KINASE C, MU; 1.
DR   PANTHER; PTHR22968:SF12; SERINE_THREONINE-PROTEIN KINASE D2; 1.
DR   Pfam; PF00130; C1_1; 2.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   PIRSF; PIRSF000552; PKC_mu_nu_D2; 1.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 2.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF57889; Cysteine-rich domain; 2.
DR   SUPFAM; SSF50729; PH domain-like; 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 2.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 2.
PE   1: Evidence at protein level;
KW   Adaptive immunity; Angiogenesis; ATP-binding; Cell adhesion; Cell membrane;
KW   Cytoplasm; Golgi apparatus; Immunity; Kinase; Magnesium; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Repeat; Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger.
FT   CHAIN           1..875
FT                   /note="Serine/threonine-protein kinase D2"
FT                   /id="PRO_0000260437"
FT   DOMAIN          398..510
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          552..808
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ZN_FING         138..188
FT                   /note="Phorbol-ester/DAG-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   ZN_FING         265..315
FT                   /note="Phorbol-ester/DAG-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   REGION          1..33
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          224..247
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           725..727
FT                   /note="Important for ABL1-mediated Tyr-718 phosphorylation"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BZL6"
FT   COMPBIAS        10..33
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        675
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         558..566
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         581
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         26
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O94806"
FT   MOD_RES         30
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O94806"
FT   MOD_RES         87
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15139"
FT   MOD_RES         197
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         198
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BZL6"
FT   MOD_RES         200
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BZL6"
FT   MOD_RES         203
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         206
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BZL6"
FT   MOD_RES         211
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         212
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BZ03"
FT   MOD_RES         214
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         244
FT                   /note="Phosphoserine; by CSNK1D and CSNK1E"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BZL6"
FT   MOD_RES         245
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BZL6"
FT   MOD_RES         408
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15139"
FT   MOD_RES         439
FT                   /note="Phosphotyrosine; by ABL1"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BZL6"
FT   MOD_RES         519
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BZL6"
FT   MOD_RES         707
FT                   /note="Phosphoserine; by PKC"
FT                   /evidence="ECO:0000250|UniProtKB:Q15139"
FT   MOD_RES         711
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         718
FT                   /note="Phosphotyrosine; by ABL1"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BZL6"
FT   MOD_RES         873
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BZL6"
SQ   SEQUENCE   875 AA;  96497 MW;  789FD9853EEDF6A1 CRC64;
     MAAAPSHPAG LPCSPGPGSP PPPGGSDLQS LPPLLPQIPA PGSGVSFHIQ IGLTREFVLL
     PAASELAHVK QLACSIVDQK FPECGFYGLY DKILLFKHDP TSANLLQLVR SAADIQEGDL
     VEVVLSASAT FEDFQIRPHA LTVHSYRAPA FCDHCGEMLF GLVRQGLKCD GCGLNYHKRC
     AFSIPNNCSG ARKRRLSSTS LASGHSVRLG SSESLPCTAE ELSRSTTDLL PRRPPSSSSS
     SSSSSFYTGR PIELDKMLMS KVKVPHTFLI HSYTRPTVCQ ACKKLLKGLF RQGLQCKDCK
     FNCHKRCATR VPNDCLGEAL INGDVPMEEA ADYSEADKSS LSDELEDSGV IPGSHAENAL
     HASEEEEGEG GKAQSSLGYI PLMRVVQSVR HTTRKSSTTL REGWVVHYSN KDTLRKRHYW
     RLDCKCITLF QNNTTNRYYK EIPLSEILAV EPAQNFSLVP PGTNPHCFEI ITANVTYFVG
     ETPGGAPGGP SGQGTEAARG WETAIRQALM PVILQDAPSA PGHTPHRQAS LSISVSNSQI
     QENVDIATVY QIFPDEVLGS GQFGVVYGGK HRKTGRDVAV KVIDKLRFPT KQESQLRNEV
     AILQSLRHPG IVNLECMFET PEKVFVVMEK LHGDMLEMIL SSEKGRLPER LTKFLITQIL
     VALRHLHFKN IVHCDLKPEN VLLASADPFP QVKLCDFGFA RIIGEKSFRR SVVGTPAYLA
     PEVLLNQGYN RSLDMWSVGV IMYVSLSGTF PFNEDEDIND QIQNAAFMYP ASPWSHISSG
     AIDLINNLLQ VKMRKRYSVD KSLSHPWLQE YQTWLDLREL EGKMGERYIT HESDDARWDQ
     FVSERHGTPA EGDLGGACLP QDHEMQGLAE RISIL
//
